Business Context and Reporting Period
Company: Bicycle Therapeutics plc (BCYC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, a novel class of medicines combining the pharmacology of biologics with the properties of small molecules. The company focuses on oncology indications. In March 2026, the company announced a strategic reprioritization of its clinical portfolio to focus on next-generation therapeutics, including nuzefatide pevedotin and Bicycle Radioconjugates (BRC), resulting in a workforce reduction of approximately 30%.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|
| Collaboration Revenue | $629 | $1,516 | $12,897 |
| Total Operating Expenses | $55,188 | $121,557 | $169,703 |
| Net Loss | $(50,333) | $(111,158) | $(139,706) |
| Net Loss Per Share (Basic & Diluted) | $(0.72) | $(1.59) | $(2.02) |
| Cash and Cash Equivalents (Balance Sheet) | $510,052 (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(115,531) (Six Months 2026) | $(159,156) (Six Months 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased significantly by $11.4 million for the six months ended June 30, 2026, compared to the prior year period. This was primarily due to the termination of collaboration agreements with Genentech (effective August 2025) and Novartis (effective February 2026).
- Expense Reduction: Total operating expenses decreased by $48.1 million year-over-year for the six-month period. Research and development (R&D) expenses dropped by $40.0 million, largely driven by reduced clinical program expenses for zelenectide pevedotin following the conversion of its registrational trial to a randomized Phase II trial and the discontinuation of certain indications. General and administrative (G&A) expenses decreased by $8.1 million.
- Workforce Reduction Impact: The company recognized $5.5 million in severance and termination benefits during the six months ended June 30, 2026, associated with the March 2026 workforce reduction. Despite these charges, overall expenses declined due to lower headcount and reduced clinical activity.
- Interest Income: Interest and other income decreased by $6.6 million year-over-year due to lower average interest rates and reduced cash balances.
Guidance, Outlook, and Risks
- Liquidity: As of June 30, 2026, the company held $510.1 million in cash and cash equivalents. Management expects this to be sufficient to fund operations and capital expenditures for at least 12 months from the filing date.
- Deferred Revenue Recognition: In July 2026, Bayer provided notice of termination of its collaboration agreement, effective September 2026. The company expects to recognize approximately $33.2 million of remaining deferred revenue in the third quarter of 2026.
- Strategic Focus: The company is deprioritizing the internal development of zelenectide pevedotin and BT7480 to focus on nuzefatide pevedotin and next-generation BRC molecules. It intends to explore partnership opportunities for BT7480.
- Risks:
- Capital Needs: The company expects to continue incurring significant losses and will require additional funding to advance clinical trials and commercialization efforts.
- Regulatory & Clinical: Success depends on the outcome of clinical trials for nuzefatide pevedotin and BT1702. Regulatory approval is uncertain.
- Collaboration Dependence: Future revenue is heavily dependent on the success of remaining collaborations (e.g., Bayer, Ionis) and the ability to secure new partnerships.
- Geopolitical & Trade: Risks include potential tariffs on pharmaceutical imports and supply chain disruptions, particularly regarding reliance on third-party manufacturers in China.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $510.1 million cash balance against the projected burn rate, considering the upcoming recognition of $33.2 million in deferred revenue from Bayer.
- Workforce Reduction Costs: Confirm the total expected severance charges ($6.5 million) and the timeline for completion of the 30% workforce reduction.
- Clinical Trial Status: Review the latest data and enrollment status for the nuzefatide pevedotin Phase II trial in pancreatic ductal adenocarcinoma and the Phase I/II trial in urothelial cancer.
- Deferred Revenue Timing: Monitor the third quarter 2026 financial results for the expected recognition of the $33.2 million Bayer deferred revenue.
- Partnership Pipeline: Assess progress in securing new collaboration partners for deprioritized assets like BT7480.